BWX Technologies, Inc. (BWXT) | The Buildout — AI Infrastructure
The Verdict
BWX Technologies makes the nuclear components, reactors and fuel that go into U.S. naval propulsion and commercial nuclear power. It is a supplier, not a reactor vendor — management describes it as a merchant supplier that sells into the reactor OEMs, the utilities and the government rather than building plants itself. For the AI buildout, that puts it one step back from the data center: the link runs through nuclear power demand, which data-center load growth helps pull forward, not through anything BWXT sells directly to AI. The company is narrowing to two cores, national security and commercial nuclear power, and is building U.S. commercial manufacturing capacity ahead of the orders it expects.
| Market Cap | — |
| Revenue (TTM) | $3.5B |
| Revenue Growth | +22.7% |
| EBITDA Margin (TTM) | 13.0% |
| Net Debt | $1.4B |
| Earnings Beats | 7 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- Backlog was $8.4B at Q2 2026, up 40% year over year, with trailing 12-month book-to-bill of 1.7x.
- Commercial Operations organic revenue grew 33% in Q2 2026 and 39% in Q1 2026; FY2026 Commercial revenue growth guidance was raised to about 45% from about 30%.
- FY2026 guidance was raised at both the Q1 and Q2 calls: adjusted EBITDA to $662–672M, non-GAAP EPS to $4.70–4.80, and free cash flow to $345–360M.
- Government Operations adjusted EBITDA margin is guided to about 20.5%, a 150 basis point increase from the start of the year that management attributes to cost performance.
- Trailing-twelve-month free cash flow converts at 95% of net income, and Q2 2026 free cash flow was $115M.
What We’re Watching
- Government Operations revenue growth guidance was cut to high single digits from low teens; management attributes it to favorable cost accounting, but the headline decelerates.
- Backlog fell sequentially to $8.4B from $8.7B in Q1 2026 — management attributes it to the timing of large multiyear awards.
- Commercial Operations margin was guided down to about 13% from about 14% on capacity and Canada investment; management expects a 2027 inflection.
- The capacity being built is orders-agnostic — management says it is building in advance of the orders — and the validating new-build order is expected before year-end 2026.
The demand thesis looks intact and, on the order book, strengthening: guidance was raised at both calls and backlog is up 40% year over year. The composition is less clean. Growth rates are decelerating off a step-change base, gross margin has compressed as mix shifts toward the lower-margin Commercial segment, and the demand the capacity is built to serve is gated by government deal structures and by utilities that describe new nuclear as early or not next. The open question is whether a commercial new-build order lands before year-end 2026.
Earnings Beat
BWXT reported Q2 2026 revenue of $902M, up 18% year over year including 9% organic growth, at a 22.4% gross margin. Government Operations revenue rose 2% at a 20.9% adjusted EBITDA margin, while Commercial Operations revenue rose 72% total and 33% organic at an 11.9% margin. Backlog stood at $8.4B, up 40% year over year, with trailing 12-month book-to-bill of 1.7x.
| Metric | Q2 FY2026 | Q1 FY2026 | Q2 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $902M | $861M | $764M | +18.0% |
| Gross margin | 22.4% | 23.0% | 25.1% | -270bps |
| EBITDA | $121M | $115M | $130M | −6.6% |
| EPS | $0.97 | $0.99 | $0.85 | +13.2% |
| Backlog | $8.4B | $8.7B | n/a | +40% |
| Book-to-bill (trailing 12-month) | 1.7x | n/a | n/a | — |
We believe the industry is in the early stages of a multi-decade super cycle of growth.— Rex D. Geveden, President & CEO, 2026-08-03
Management tone: Management's framing escalated across the two calls in the source. The Q1 2026 call leaned on "record backlog, unprecedented demand"; by the Q2 call the language had hardened to structural, describing the industry as being in the early stages of a multi-decade super cycle and BWXT's role as a super merchant supplier for critical nuclear technologies. Management answered most analyst questions directly, including why no firm U.S. AP1000 order has been placed, and was candid about soft spots — calling nuclear project delivery the biggest risk in the market and saying the company was not yet ready to make a full capital commitment on TRISO.
Management Guidance
For FY2026, management guides revenue of approximately $3.8B, adjusted EBITDA of $662–672M, non-GAAP EPS of $4.70–4.80, and free cash flow of $345–360M, with capital expenditures at about 6% of sales. Two segment lines moved in opposite directions. Government Operations revenue growth was cut to high single digits from low teens while its margin was raised to about 20.5% from above 19% — management attributes the reversal to improved cost performance that lowers reported revenue under its accounting rules. Commercial Operations revenue growth was raised to about 45% from about 30%, with slightly more than half the increase from the PCG acquisition, while its margin was cut to about 13% from about 14% on U.S. capacity and Canada investment. No 2027 guidance was set.
Trajectory
Revenue grew 18% year over year in Q2 2026 to $902M, against 26% in Q1 2026. The mix is shifting toward the faster-growing, lower-margin Commercial segment: Commercial organic revenue rose 33% in Q2 and 39% in Q1, while Government Operations grew 2% in Q2. Government Operations ran a 20.9% adjusted EBITDA margin and Commercial Operations an 11.9% margin. Gross margin was 22.4% in Q2 2026, down from 25.1% a year earlier, and free cash flow was $115M.
The Model
The model projects FY+1 revenue of $3,815M and EBITDA of $673M, a 17.65% margin, and FY+2 revenue of $4,175M and EBITDA of $758M, an 18.15% margin. The near-term anchor is the FY2026 guidance range and an order book at roughly 2.2 years of revenue at the current run rate. FY+2 depends on Commercial Operations growth holding near its guided level, on HPDU and newer government programs ramping, and on whether new-build equipment orders begin to convert into backlog.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $3.2B | $3.8B | $4.2B |
| YoY Growth | — | +19.3% | +9.4% |
| EBITDA | $472M | $673M | $758M |
| EBITDA Margin | 14.8% | 17.6% | 18.1% |
Projections are the median of 4 independent model runs. The model’s revenue sits 1.7% above analyst consensus.
For FY2026, management guides revenue of approximately $3.8B, adjusted EBITDA of $662–672M, non-GAAP EPS of $4.70–4.80, and free cash flow of $345–360M, with capital expenditures at about 6% of sales. Two segment lines moved in opposite directions. Government Operations revenue growth was cut to high single digits from low teens while its margin was raised to about 20.5% from above 19% — management attributes the reversal to improved cost performance that lowers reported revenue under its accounting rules. Commercial Operations revenue growth was raised to about 45% from about 30%, with slightly more than half the increase from the PCG acquisition, while its margin was cut to about 13% from about 14% on U.S. capacity and Canada investment. No 2027 guidance was set.
What Could Go Right — and Wrong
- At least one new-build nuclear equipment order is secured before year-end 2026, validating the commercial capacity investment.
- A final investment decision on the U.S. commercial manufacturing site makes the largest visible capital commitment concrete.
- Commercial Operations margin inflects in 2027 as capacity investment slows and PCG utilization rises from about 50%.
- HPDU and newer government programs ramp into second-half 2026 revenue, and legacy-priced backlog burns off by end-2026, lifting Government margin.
- A TRISO capital commitment follows the Janus selection, turning a market management calls highly uncertain into committed capacity.
- The year-end new-build order does not land, leaving capacity built ahead of demand with no near-term offset.
- Backlog declines for a second consecutive quarter, turning award timing into a trend.
- Commercial margin stays below guidance as capacity investment continues and PCG utilization ramps slowly.
- New-build demand slips further as utilities keep waiting on government special-purpose-vehicle deal structures.
- Consolidated margin compresses further as revenue mix shifts toward the lower-margin Commercial segment faster than Government execution gains offset it.
Looking Ahead
Over the next twelve months, the milestones management has set are specific: an Investor Day on September 29, 2026, at least one new-build nuclear equipment order before year-end 2026, a final investment decision on U.S. commercial capacity "in the coming months," an operational prototype centrifuge in 2026, and a meaningful HPDU contribution to second-half Government Operations revenue. The medical sale to Nordic Capital is also pending, with no close date specified.
- September 29, 2026Investor Day — Longer-term targets and capital framework, in New York City.
- Before year-end 2026New-build order — At least one new-build nuclear equipment order expected.
- Coming monthsCapacity FID — Final investment decision on the U.S. commercial capacity site.
- 2026Centrifuge prototype — Operational prototype centrifuge targeted for delivery this year.
- H2 2026HPDU revenue ramp — New HPDU plants expected to lift Government Operations revenue.
- Early 2030sCanada long-lead demand — Canadian large-reactor long-lead orders expected to reach BWXT.
Financials
Annual Summary
| Metric | FY2024 | FY2025 | TTM | YoY |
|---|---|---|---|---|
| Revenue | $2.7B | $3.2B | $3.5B | +18.3% |
| Gross Margin | 24.3% | 23.0% | 22.0% | 125bps |
| EBITDA | $466M | $472M | $458M | +1.2% |
| EBITDA Margin | 17.2% | 14.8% | 13.0% | 250bps |
| Net Income | $282M | $329M | $355M | +16.7% |
| Free Cash Flow | $255M | $295M | $317M | — |
| Net Cash | — | — | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)22.0%
- EBITDA Margin (TTM)13.0%
- Net Margin (TTM)10.1%
- ROIC9.8%
- FCF Conversion69.2%
- SBC / Revenue0.9%
The Company
BWX Technologies is, in its own filing language, "a specialty manufacturer of nuclear components, a developer of nuclear technologies and a service provider with an operating history of more than 100 years." Its core business is the design, engineering and manufacture of precision naval nuclear components, reactors and nuclear fuel for the U.S. Government, alongside special nuclear materials processing, products and services to the nuclear power industry and advanced nuclear technologies. It sells to the reactor OEMs, to utilities and to the government as a component, fuel and services supplier rather than as a reactor vendor — management describes it as a merchant supplier that participates across the nuclear value chain rather than betting on a single reactor design.
The company runs about 11,000 employees across two reporting segments. Government Operations manufacturing is U.S.-based and owned: Lynchburg, Virginia; Barberton and Euclid, Ohio; Mount Vernon, Indiana; and Erwin and Jonesborough, Tennessee. Commercial Operations manufacturing is concentrated in Canada, at Cambridge and Etobicoke, Ontario (owned) plus several leased Ontario and Vancouver sites. Net property, plant and equipment of $1,596M splits roughly 55% United States and 44% Canada. Management says the company has delivered 420 essentially small modular reactors over the last 50 years.
Business Segments
Competitive Landscape
The 10-K names competitors in both segments. In Government Operations: Bechtel National, Amentum Environment & Energy, Fluor, Northrop Grumman, Huntington Ingalls, Honeywell, Leidos, Westinghouse Electric and AtkinsRéalis. In Commercial Operations: Framatome, Cameco, Doosan Heavy Industries & Construction, AECON Group, Westinghouse Electric and AtkinsRéalis. On large components, management says its capabilities compare favorably with "the largest industrial players, the Doosans and the [NNSAs] of the world," and describes BWXT as "the last man standing in commercial capability in North America." Management says BWXT is the only producer of TRISO fuel at any scale, while noting TRISO X and Standard Nuclear among new entrants.
- Westinghouse ElectricNamed in filings as a competitor in both segments. Management said it is "in touch with the top leadership" on AP1000 opportunities, making Westinghouse both a competitor and a potential customer.
- FramatomeNamed in filings as a Commercial Operations competitor; also the Isogen joint venture partner, which is excluded from the medical sale.
- Huntington IngallsNamed in filings as a Government Operations competitor; not discussed.
- FluorNamed in filings as a Government Operations competitor; not discussed.
- Doosan Heavy Industries & ConstructionNamed in filings as a Commercial Operations competitor; management cites "the Doosans" among the large industrial players it compares favorably with.
Supply Chain
BWXT buys specialty alloys and sells nuclear components, fuel and services into reactor OEMs, utilities and the U.S. Government. Its one verified supplier relationship is ATI, which supplies zirconium, nickel and titanium alloys under a five-year agreement through 2030.
More on BWXT: Earnings recap